← ANALYST RATINGS · TIPRANKS
Caris Life Sciences, Inc. (CAI): analyst forecast and price target
Analyst consensus
Moderate Buy5 Buy2 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $29.71, the highest $36.00, the lowest $21.00. The average is −2.8% from the last price of $30.56.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $25.00 → $35.00+40.0% | Buy | +14.5% | Reiterated | 14.10.26on TipRanks 06:10 | +3.5%next day +4.7% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $30.00 → $36.00+20.0% | Buy | +17.8% | Reiterated | 13.10.26on TipRanks 08:41 | −0.5%next day +3.5% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $23.00 → $35.00+52.2% | Buy | +14.5% | Reiterated | 09.10.26on TipRanks 08:25 | +7.4%next day 0.0% · 5 days +4.9% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $27.00 → $35.00+29.6% | Buy | +14.5% | Reiterated | 20.09.26on TipRanks Sep 21 08:15 | +0.7%next day +2.7% · 5 days +4.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $33.00+10.0% | Hold | +8.0% | Reiterated | 18.09.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $31.00 → $34.00+9.7% | Buy | +11.3% | Reiterated | 18.09.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $32.00+10.3% | Hold | +4.7% | Reiterated | 18.09.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $33.00+13.8% | Hold | +8.0% | Reiterated | 18.09.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $34.00+9.7% | Buy | +11.3% | Reiterated | 18.09.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $33.00+13.8% | Hold | +8.0% | Reiterated | 18.09.26on TipRanks 07:05 | — | |
| Unknown Analyst | UBS | $28.00 | Hold | −8.4% | Initiated | 08.09.26on TipRanks Sep 14 09:30 | −0.4%next day −2.7% · 5 days +15.9% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $32.00 → $33.00+3.1% | Buy | +8.0% | Reiterated | 07.08.26on TipRanks 07:10 | +13.1%next day +2.9% · 5 days −4.5% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $25.00 → $26.00+4.0% | Buy | −14.9% | Reiterated | 06.08.26on TipRanks 07:55 | +21.7%next day +13.1% · 5 days +9.7% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $21.00 | Hold | −31.3% | Reiterated | 06.08.26on TipRanks 07:45 | +21.7%next day +13.1% · 5 days +9.7% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $22.00 | Hold | −28.0% | Reiterated | 06.08.26on TipRanks 07:06 | +21.7%next day +13.1% · 5 days +9.7% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | — | Hold | — | Downgrade | 01.06.26on TipRanks 16:10 | +0.3%next day −5.6% · 5 days +5.6% | ↗ |
| Unknown Analyst | Guggenheim | $36.00 | Buy | +17.8% | Reiterated | 11.05.26on TipRanks May 12 02:15 | −1.5%next day +5.3% · 5 days −5.2% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $28.00 → $22.00−21.4% | Buy | −28.0% | Reiterated | 08.05.26on TipRanks 08:50 | −19.4%next day −1.5% · 5 days −10.1% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $35.00 → $28.00−20.0% | Buy | −8.4% | Reiterated | 08.05.26on TipRanks 07:05 | −19.4%next day −1.5% · 5 days −10.1% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $28.00 | Buy | −8.4% | Initiated | 12.04.26on TipRanks 19:50 | +5.0%next day +4.3% · 5 days +7.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Caris Life Sciences, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 09.10.26: target $28.33 at a price of $27.50 (+3.0%); now: $30.11 at $30.56 (−1.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 3 | 3 | 0 |
| Buy | 3 | 3 | 5 | 7 | 8 | 7 |
| Hold | 5 | 5 | 5 | 4 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.03 (from $0.00 to $0.08). Last quarter: $0.00.
Sales
Next quarter’s sales estimate — $255M (from $243M to $264M). Last quarter: $264M.
Best top-analyst consensus in the sector · General
About Caris Life Sciences, Inc.
- CEO: David Dean Halbert
- Employees: 1,846
- 750 West John Carpenter Freeway, Irving, TX, 75039, US
- www.carislifesciences.com
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗